State of the Science Summit on Genitourinary Cancers

Nancy B. Davis, MD, discusses the excitement with targeted therapies as well as anticipated combination strategies under investigation in advanced urothelial cancer.

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.

Eric Shinohara, MD, MSCI, discusses the emergence of stereotactic body radiotherapy to treat patients with prostate cancer.

David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the use of immunotherapy after progression on platinum-based therapy in advanced bladder cancer.

Manoj K. Jain, MD, discusses new imaging modalities and what they could mean for the field going forward.

Randal Henderson, MD, MBA, discusses the data that led to the PCORI-funded trial, what the results could mean for the field, and interesting research on the horizon.

Parminder Singh, MD, discusses ongoing research in advanced urothelial cancer and the focus on incorporating precision medicine in the field.

Manish Kohli, MD, discusses the agents that have redefined the treatment paradigm of metastatic prostate cancer and details ongoing work to elucidate genomic classifiers.

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in metastatic renal cell carcinoma (mRCC).

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology and associate medical director at the University of Florida Health Proton Therapy Institute, discusses the potential benefits of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

David D. Thiel, MD, provides perspective on the CARMENA findings in metastatic renal cell carcinoma.

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses the indications for PET imaging in prostate cancer.

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses the benefits of proton therapy in prostate cancer.

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the advancements in surgical techniques for renal cell carcinoma.

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses imaging modalities in prostate cancer.

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses new imaging modalities to detect disease in patients with prostate cancer.

Winston Tan, MD, discusses the influx of treatment options in nonmetastatic castration-resistant prostate cancer and the modalities that are being used in an effort to ensure their optimal use.

Richard W. Joseph, MD, discusses the factors that must be considered when selecting the appropriate frontline treatment for patients with metastatic renal cell carcinoma, the need for clarity regarding the role of cytoreductive nephrectomy, as well as the research that is being done in those with rarer subtypes of kidney cancer.

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses resectability in metastatic renal cell carcinoma (mRCC).

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses investigational immunotherapy combinations in urothelial cancer.

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the process of selecting frontline therapy in metastatic renal cell carcinoma (mRCC).

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the phase III randomized CARMENA trial, which examined cytoreductive nephrectomy plus sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma.

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the prevalence of genomic testing in urothelial cancer.

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the goals of androgen deprivation therapy (ADT) in the treatment of patients with prostate cancer.